TriangleNemtabrutinib (NCT07673367)
Nemtabrutinib trial for Recurrent Mantle Cell Lymphoma (NCT07673367). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory mantle cell lymphoma eligible for brexucabtagene autoleucel. Disease refractory to a noncovalent BTK inhibitor is excluded.
The idea: nemtabrutinib blocks BTK signaling; CAR T cells are modified to attack cancer. Oral nemtabrutinib starts before apheresis, pauses for lymphodepleting chemotherapy and the cell infusion, then can restart around day 28 if disease has not progressed. Treatment may continue for two years. Researchers track progression-free survival and safety.
This phase 2 study plans 25 patients. Bhagirathbhai Dholaria leads at Vanderbilt in Nashville, one recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.